Robotic surgery as effective as open surgery for bladder cancer

Robotic surgery is as effective as traditional open surgery in treating bladder cancer, according to a landmark study published in the journal Lancet.

Three Loyola Medicine urologists, Marcus Quek, MD, Gopal Gupta, MD, and Alex Gorbonos, MD, are co-authors of the study. First author is Dipen Parekh, MD, of the University of Miami.

Loyola is among 15 centers that participated in the nationwide trial of 350 patients, who were randomly assigned to undergo or to remove cancerous bladders.

After two years, there was no significant difference between the two groups in survival without disease progression. Robotic was associated with less blood loss and shorter hospital stays, but longer surgeries. There were no significant differences in complication rates or in patients' quality of life. The study is called RAZOR (randomized open versus robotic cystectomy trial) and was funded by the National Cancer Institute.

A robotic system allows a surgeon to perform operations through a few small incisions. Movements by the surgeon's hand or wrist are translated into highly precise movements of the surgical instruments. Every maneuver is directed by the surgeon, in real time, as the surgeon views a magnified, 3-D, high-definition image of the surgical site.

Since robotic surgery was introduced in 2000, it has spread rapidly and has been used in about four million surgeries worldwide. But apart from the RAZOR trial, there have been no prospective, randomized multicenter trials to assess how robotic surgery compares to open surgery in cancer survival.

The RAZOR trial found that two years after surgery, 72.3 percent of patients in the robotic surgery group were alive, with no and essentially cured, compared with 71.6 percent in the open surgery group. Sixty-seven percent of robotic surgery patients experienced adverse effects such as urinary tract infections and intestinal obstructions, compared with 69 percent in the open surgery group.

Robotic surgery patients stayed a median of six days in the hospital, compared with seven days in the open surgery group. Robotic surgery patients lost less than half as much blood as open surgery patients, but spent more time in the operating room (seven hours, eight minutes compared with six hours, one minute).

Researchers wrote that the findings "underscore the need for further high-quality trials to assess surgical innovation before this surgical technique is widely adopted in clinical practice."

Dr. Gupta added that the study provides evidence demonstrating that the robotic approach performs at least as well as the open approach. "It is important to conduct these trials before widespread adoption of technology, as has been the case with (removal of the prostate)," he said.

The study is titled "Robot-assisted radical cystectomy versus open radical cystectomy in patients with (RAZOR): an open-label, randomized, phase 3, non-inferiority trial."


Explore further

First major study comparing robotic to open surgery published in The Lancet

More information: Dipen J Parekh et al, Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial, The Lancet (2018). DOI: 10.1016/S0140-6736(18)30996-6
Provided by Loyola University Health System
Citation: Robotic surgery as effective as open surgery for bladder cancer (2018, July 11) retrieved 20 February 2019 from https://medicalxpress.com/news/2018-07-robotic-surgery-effective-bladder-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more